Journal: eLife

Article Title: A fusion peptide in preS1 and the human protein disulfide isomerase ERp57 are involved in hepatitis B virus membrane fusion process

doi: 10.7554/eLife.64507

Figure Lengend Snippet:

Article Snippet: 293T human kidney cells (ATCC CRL-1573), CHO-K1 (CHO) Chinese hamster ovary cells (ATCC CCL-61), and CHO-pgsB-618 cells (ATCC CRL-2241), which do not produce glycosaminoglycans, were grown in Dulbecco’s modified minimal essential medium (DMEM, Gibco) supplemented with 100 U/ml of penicillin, 100 μg/ml of streptomycin, and 10% fetal calf serum.

Techniques: Virus, Produced, Variant Assay, Construct, Generated, Transduction, Retroviral, Plasmid Preparation, Selection, shRNA, Transfection, Expressing, Clone Assay, Luciferase, Isolation, Sequencing, Mutagenesis, Reporter Assay, Activity Assay, cDNA Synthesis, SYBR Green Assay, Membrane, Integrity Assay, Cytotoxicity Assay, Software, Staining, RNA Extraction

Journal:

Article Title: YPEL3, a p53-regulated gene that induces cellular senescence

doi: 10.1158/0008-5472.CAN-09-3219

Figure Lengend Snippet: YPEL3 expression is reduced in ovarian tumors and inhibition of CpG hypermethylation leads to increased YPLE3 mRNA in ovarian cell lines. (A) RT-PCR analysis of YPEL3 mRNA expression in 30 ovarian tumor and 6 normal ovarian samples obtained from Origene TissueScan Ovarian Cancer Array HORT101. (B) RT-PCR analysis of YPEL3 mRNA expression in platinum-sensitive ovarian cell line, A2780 and two cisplatin resistant ovarian cell lines, C30 and Cp70 after treatment with varying doses of 5-aza-deoxycytidine. (C) Analysis of CpG island upstream of YPEL3 promoter in 5-aza-dC treated Cp70 cells. PCR fragments (A-D) span -1222 to -8 relative to the start site of transcription. Bisulfite treated genomic DNA from treated (10 μM 5-aza-dC) or untreated Cp70 cells were used in PCR amplifications. Between 5-7 PCR inserts were DNA sequenced for each PCR fragment.

Article Snippet: The decreased expression of YPEL3 in both human tumors and human tumor cell lines provide further support that YPEL3 possesses tumor suppressor-type activity. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 6 caption a7 YPEL3 expression is reduced in ovarian tumors and inhibition of CpG hypermethylation leads to increased YPLE3 mRNA in ovarian cell lines. (A) RT-PCR analysis of YPEL3 mRNA expression in 30 ovarian tumor and 6 normal ovarian samples obtained from Origene TissueScan Ovarian Cancer Array HORT101. (B) RT-PCR analysis of YPEL3 mRNA expression in platinum-sensitive ovarian cell line, A2780 and two cisplatin resistant ovarian cell lines, C30 and Cp70 after treatment with varying doses of 5-aza-deoxycytidine. (C) Analysis of CpG island upstream of YPEL3 promoter in 5-aza-dC treated Cp70 cells.

Techniques: Expressing, Inhibition, Reverse Transcription Polymerase Chain Reaction